Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Combination Overcomes Breast Cancer Resistance… >
Combination Overcomes Breast Cancer Resistance to Herceptin

Published: March 14, 2011.
By University of Texas M. D. Anderson Cancer Center
http://www.mdanderson.org

HOUSTON - Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

Adding the drug saracatinib to Herceptin treatment shrinks previously resistant tumors by cutting off at least five different molecular pathways, each of which can resist, said senior author Dihua Yu, M.D., Ph.D., professor in MD Anderson's Department of Molecular and Cellular Oncology.

"Scientists have identified so many ways by which a tumor resists Herceptin that it raises an important issue for treatment," Yu said. "Will we have to give patients six drugs or 10 drugs to block them all? The side effects would be awful. Two pills are better. This combination is a promising therapy for those with Herceptin-resistant breast cancer."

Working in cell lines, mouse models of breast cancer and checking their work in human tumor samples, Yu and colleagues identified SRC, a known cancer-promoting protein, as the crucial common downstream component of multiple resistance pathways.

Saracatinib is an SRC inhibitor, thwarting that protein and allowing Herceptin to work again in tumors that have a high amount of the HER2 protein.

Only about 26 percent of women with HER2-positive breast cancer respond to Herceptin as single therapy. Between 40 and 60 percent respond to the drug when combined with other chemotherapy.

Combination is ready for clinical trials

Yu said saracatinib has been tested in phase I and phase II clinical trials as a single treatment against late-stage cancers. It has a favorable side effects profile.

"It didn't work as a single agent, but very few drugs work by themselves against late stage disease," Yu said. "Our experiments confirmed its lack of efficacy as a sole treatment. But combined with Herceptin, it's beautiful."

Another SRC inhibitor, dasatinib, has been approved by the U.S. Food and Drug Administration as an anti-cancer drug, but it has harsher side effects, said Siyuan Zhang, Ph.D., a postdoctoral fellow in Yu's lab and the paper's first author.

A tumor-suppressor's job

In 2004, Yu's lab discovered that loss of the tumor-suppressing gene known as PTEN led to Herceptin-resistant tumors. PTEN is a phosphotase - a protein whose function is to strip phosphate chemical groups off of other molecules.

PTEN has two components, one to remove phosphate groups from lipids, and another to remove them from proteins. PTEN's target protein however, was unknown.

Zhang discovered that SRC is a PTEN target. With its phosphate groups, SRC is active. PTEN stifles SRC by peeling away the phosphates.

If PTEN loss leads to Herceptin resistance, and PTEN targets SRC, would that make SRC the culprit?

On the trail of SRC

In a series of experiments the researchers found:

  • SRC is active in breast cancer cells once vulnerable but now resistant to Herceptin and in cells that are resistant from the start.
  • Activation of SRC drives resistance to Herceptin. Tumors with low SRC levels treated by Herceptin shrunk to 20 percent of their original volume in 21 days while SRC-heavy tumors increased by nearly 400 percent over the same time in mouse experiments.
  • SRC activity correlates with patient response to Herceptin. Assessing SRC activation in samples of 57 human breast cancer tumors, the team found that more than 90 percent of tumors with low SRC responded compared with 40 percent of tumors with active SRC.
  • Patients with little active SRC had a median survival of 57.9 months compared with 34.2 months in those with high SRC activity.
  • SRC is activated by a number of receptor tyrosine kinases that cause resistance, including IGF-1R, EGFR, ERBB2, HER3, and Met, separate pathways that work through SRC. "Block SRC, and you reverse them all," Zhang said.


Crushing resistance

Combining Herceptin and saracatinib to treat resistant tumors in mice reduced tumor volume by 90 percent in 25 days. Herceptin alone kept tumor volume about the same during the same period, while control and saracatinib alone permitted growth of more than 200 percent.

The difference was more striking in tumors deficient in SRC's enemy, the PTEN tumor-suppressor. The combination reduced tumor volume by more than 90 percent while the two drugs alone allowed growth of between 200 and 400 percent.

This study was funded by grants from the National Cancer Institute, MD Anderson Breast Specialized Program of Research Excellence; Department of Defense Center of Excellence; Susan G. Komen Breast Cancer Foundation Promise Grant; the Cancer Prevention and Research Institute of Texas, the MD Anderson Breast SPORE Career Development Award and Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the ScienceNewsline.
Related »

Breast 
11/14/11 
Signaling Pathway Linked to Inflammatory Breast Cancer May Drive Disease Metastasis
By American Association for Cancer Research
Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients …
Cancer 
11/14/11 
George Mason University Research Gives Hope to Women with Deadliest Breast Cancer
By George Mason University
Women with the deadliest and rarest form of breast cancer now have a chance of treatment where once their options were severely limited, thanks to a new discovery by …
Treatment 
5/25/10 
RCSI Researchers Uncover Breakthrough in Predicting Severity of Breast Cancer
By Royal College of Surgeons in Ireland (RCSI)
Researchers from the Royal College of Surgeons in Ireland (RCSI) have identified a biomarker in patient blood which can predict the severity of breast cancer in patients and may …
Cancer 
5/2/13 
Study Opens New Prospects for Developing New Targeted Therapies for Breast Cancer
By European Society for Medical Oncology
Lugano-CH, Brussels-BE, 2 May 2013 -- A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted …
Disease 
12/23/11 
UK Researchers Present Findings from Kentucky Breast Cancer Patients with Disease Relapse
By University of Kentucky
The University of Kentucky Markey Cancer Center breast oncologist Dr. Suleiman Massarweh and his research team presented findings from their studies on relapse of breast cancer at the San …
Test 
4/15/14 
Blood Test Spots Recurrent Breast Cancers And Monitors Response to Treatment
By Johns Hopkins Medicine
Johns Hopkins Kimmel Cancer Center investigators report they have designed a blood test that accurately detects the presence of advanced breast cancer and also holds promise for precisely monitoring …
Treatments 
3/11/10 
Effort Aims to Spike Breast Cancer with New Approach
By The Translational Genomics Research Institute
SCOTTSDALE, Ariz. — March 11, 2010 — Many women live with breast cancer that does not respond to standard medical treatment, a condition that researchers at the Virginia G. …
Cancer 
6/5/13 
Metastatic Breast Cancer Study Shows Success in Finding New Treatment
By George Mason University
Funded by volleyball tournaments, a new study released this week shows success in pinpointing individualized treatment for women with metastatic breast cancer, according to George Mason University researchers. …
Cancer 
12/8/11 
Exemestane Plus Everolimus Increased Progression-free Survival
By American Association for Cancer Research
Everolimus in combination with exemestane has shown promise for the treatment of breast cancer. …
Breast 
7/19/13 
Alternative Target for Breast Cancer Drugs
By European Molecular Biology Organization
HEIDELBERG, 19 July 2013 – Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new …
Breast 
11/14/13 

Early Stages of Breast Cancer Could Soon Be Diagnosed from Blood Samples
By Houston Methodist
Cancer 
3/23/10 
Scott & White Healthcare Researchers Studying Investigational Agent That Targets Breast Cancer
By Scott & White Healthcare
Scott & White Healthcare researchers are studying an investigational agent that targets metastatic breast cancer to find if it can stop cancer cells from continuing to grow. Breast …
More » 

Most Popular - Medicine »
MARIJUANA »
Casual Marijuana Use Linked to Brain Abnormalities in Students
CHICAGO --- Young adults who used marijuana only recreationally showed significant abnormalities in two key brain regions that are important in emotion and motivation, scientists report. The study was …
TUMORS »
The Immune System's Redesigned Role in Fighting Cancerous Tumors
LOS ANGELES (March 11, 2014) – Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. …
INFLUENZA »
Ginseng Can Treat And Prevent Influenza And RSV, Researcher Finds
ATLANTA--Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist …
MUTATIONS »
Applying Math to Biology: Software Identifies Disease-causing Mutations in Undiagnosed Illnesses
(SALT LAKE CITY)–A computational tool developed at the University of Utah (U of U) has successfully identified diseases with unknown gene mutations in three separate cases, U of U …
PROTEINS »
MSU Physicists Push New Parkinson's Treatment Toward Clinical Trials
ScienceNewsline  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese
The selection and placement of stories are determined automatically by a computer program. All contents are copyright of their owners except U.S. Government works. U.S. Government works are assumed to be in the public domain unless otherwise noted. Everything else copyright ScienceNewsline.